Bay Area life sciences firms raise $6.1B as three companies go public

The 23 companies span cancer treatments, plant genetics and robotic lung devices. Combined, they pulled in just over $6.1 billion last year.
Fierce Biotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO

Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. The company, which specializes in designing ...
BioPharma Dive

Generate caps a strong month for biotech IPOs with $400M offering

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.
Fintel on MSN

Roivant Sciences (ROIV) price target increased by 18.98% to 32.44

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...